RTP Mobile Logo

Saturday, November 18, 2017, Santa Monica, CA - 8:00 AM – 4:00 PM (Pacific Time)

Year in Review — A Multitumor Regional Symposia Series Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers

Event Details

Date:
Saturday, November 18, 2017

Program Time:
8:00 AM – 4:00 PM (Pacific Time)
Breakfast and lunch to be provided

Location:
Fairmont Miramar Hotel & Bungalows
101 Wilshire Blvd
Santa Monica, CA 90401
Hotel phone: (310) 576-7777

Meeting Room:
Starlight Ballroom (Lobby Level)

Hotel Accommodations:
A special rate of $299 (Standard Deluxe Room) has been arranged for meeting attendees. Please see the Location tab for additional details.

 
There is no registration fee for this event. Seating is limited to clinicians in practice. Preregistration is required.


Faculty:
Lung Cancer

Matthew A Gubens, MD, MS
Associate Professor of Medicine
Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Nasser H Hanna, MD
Associate Professor of Medicine
Indiana University
Indianapolis, Indiana

Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

Breast Cancer

Harold J Burstein, MD, PhD
Associate Professor of Medicine
Harvard Medical School
Breast Oncology Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Hope S Rugo, MD
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Acute Leukemias

Hagop M Kantarjian, MD
Chairman and Professor, Leukemia Department
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Richard M Stone, MD
Director, Adult Leukemia Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Ovarian Cancer

Ursula A Matulonis, MD
Medical Director and Program Leader
Gynecologic Oncology Program
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Angeles Alvarez Secord, MD, MHSc
Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Duke Cancer Institute
Durham, North Carolina

Genitourinary Cancers

Charles G Drake, MD, PhD
Professor of Medicine
Co-Director, Cancer Immunotherapy Programs
Columbia University Medical Center
New York, New York

Robert Dreicer, MD, MS
Division of Hematology and Oncology
Department of Medicine
University of Virginia School of Medicine
Charlottesville, Virginia

Hodgkin and Non-Hodgkin Lymphomas/Chronic Lymphocytic Leukemia

Jeremy Abramson, MD
Director of the Lymphoma Program
Jon and Jo Ann Hagler Chair in Lymphoma
Massachusetts General Hospital Cancer Center
Assistant Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Loretta J Nastoupil, MD
Assistant Professor
Department of Lymphoma/Myeloma
Division of Cancer Medicine
Director, Lymphoma Outcomes Database
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Andrew D Zelenetz, MD, PhD
Medical Director, Medical Informatics
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Gastrointestinal Cancers

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Alan P Venook, MD
Professor of Clinical Medicine
University of California, San Francisco
San Francisco, California

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

 

Agenda

Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. All events will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided).

MODULE 1: Lung Cancer 8:05 AM – 9:20 AM

  • First-line treatment options for patients with EGFR mutation-positive disease; potential implications of the Phase III FLAURA trial results
  • Available efficacy and safety data with osimertinib; effectiveness in patients with CNS metastases
  • Selection of first-, second- and later-line therapy for patients with ALK- or ROS1-positive disease; implications of recent data sets and drug approvals
  • Recent FDA approval of dabrafenib/trametinib for patients with BRAF V600E tumor mutations
  • Potential treatment options for patients with other oncogenic mutations (eg, HER2, MET exon 14, RET, NTRK gene fusions)
  • Design, efficacy endpoints and available data from the PACIFIC trial evaluating the use of durvalumab as sequential therapy for patients with locally advanced disease after completion of definitive chemoradiation therapy
  • Available data with and patient selection for pembrolizumab with and without chemotherapy in individuals with newly diagnosed metastatic non-small cell lung cancer (NSCLC)
  • Ongoing trials of anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic, chemotherapeutic or targeted approaches
  • Selection of first-line therapy for patients with PD-L1-negative squamous NSCLC
  • Rational integration of ramucirumab into the management of nonsquamous and squamous NSCLC
  • Novel agents under evaluation in small cell lung cancer and malignant pleural mesothelioma

MODULE 2: Breast Cancer 9:20 AM – 10:10 AM

  • Available and emerging data guiding the use of genomic assays to optimize decision-making regarding adjuvant chemotherapy and extended endocrine therapy
  • Factors affecting the selection and sequence of systemic therapy for ER-positive metastatic breast cancer (mBC)
  • FDA approval of ribociclib and integration of CDK4/6 inhibitors into clinical algorithms for patients with ER-positive mBC
  • Recent FDA approval of and Phase III efficacy and safety findings with abemaciclib in ER-positive mBC
  • Results and clinical implications of the Phase III APHINITY trial comparing adjuvant chemotherapy/trastuzumab to chemotherapy/trastuzumab/pertuzumab for HER2-positive early BC
  • Recent FDA approval of neratinib as extended adjuvant therapy: Patient selection and use in clinical practice
  • Ongoing and planned clinical trials incorporating novel HER2-directed therapies in the neoadjuvant and adjuvant settings
  • Published data examining the use of combined endocrine and anti-HER2 blockade for triple-positive mBC
  • Diagnostic and therapeutic implications of the OlympiAD trial documenting a progression-free survival advantage with olaparib versus chemotherapy for patients with germline BRCA mutation-positive, HER2-negative mBC
  • Available data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with other systemic agents
  • Other novel agents and approaches under investigation for HER2-positive and triple-negative BC

MODULE 3: Acute Leukemias10:25 AM – 11:15 AM

  • Evidence-based induction regimens and postinduction consolidation and/or maintenance therapy for younger/fit patients with acute myeloid leukemia (AML)
  • Optimal integration of CPX-351 into the treatment of newly diagnosed therapy-related AML or AML with myelodysplasia-related changes
  • Indications for the use of hypomethylating agents as induction and/or maintenance therapy in elderly patients or those with poor-risk AML
  • FDA approval of midostaurin for patients with newly diagnosed AML and a FLT3 mutation; patient selection and practical aspects related to its administration
  • Mechanisms of action and available research data with the recently FDA-approved IDH1/2 inhibitor enasidenib; ongoing evaluation of novel IDH1/2 (eg, ivosidenib [AG-120]) and FLT3 (eg, gilteritinib, quizartinib) inhibitors in AML
  • Recent FDA approval and current clinical role of gemtuzumab ozogamicin for CD33-positive AML
  • Other novel agents under evaluation in AML (eg, venetoclax, pracinostat, GMI-1271)
  • Selection and sequencing of therapy for patients with Philadelphia chromosome-positive and negative acute lymphoblastic leukemia (ALL)
  • FDA approval of CAR T-cell therapy for pediatric and young adult patients with ALL that is refractory or in second or later relapse; ongoing clinical investigation for older adult patients
  • Clinical experience with different preparations of asparaginase in young adult and adult patients with ALL
  • Patient selection for blinatumomab in ALL clinical practice
  • Available research data supporting the recent FDA approval of inotuzumab ozogamicin in R/R B-cell precursor ALL
  • Diagnostic considerations for acute promyelocytic leukemia (APL); investigational approaches for low/intermediate-risk disease; choice of induction regimen for patients with high-risk disease

MODULE 4: Ovarian Cancer 11:15 AM – 12:05 PM

  • Similarities and differences between available genetic testing platforms; role of extended panel testing/next-generation sequencing
  • Identification of “BRCA-like” and other genomic signatures (eg, homologous recombination deficiency) that may predict benefit from PARP inhibition
  • Optimal integration of niraparib, olaparib and rucaparib into current ovarian cancer (OC) treatment algorithms; ongoing evaluation of investigational PARP inhibitors
  • Clinical role of niraparib and olaparib as maintenance therapy; Phase III study results with maintenance rucaparib
  • Recognition and management of PARP inhibitor-related side effects (anemia, GI toxicity, pneumonitis, et cetera)
  • Patient selection for neoadjuvant systemic therapy; available data defining the optimal neoadjuvant regimen
  • Risks and benefits of intraperitoneal chemotherapy; indications for its use in clinical practice
  • Optimal integration of bevacizumab in combination with chemotherapy followed by maintenance bevacizumab into the treatment algorithm for patients with platinum-sensitive recurrent OC
  • Mechanism of action of, available efficacy data with and ongoing trials evaluating the role of mirvetuximab soravtansine
  • Available safety and efficacy data with and ongoing trials evaluating anti-PD-1/PD-L1 antibodies in patients with OC

MODULE 5: Genitourinary Cancers 12:50 PM – 1:40 PM

  • Research database supporting the recent FDA approvals of atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab in urothelial bladder cancer (UBC); patient selection for and use of these agents in clinical practice
  • Active and planned clinical trials of immune checkpoint inhibitors alone or in combination for early and advanced UBC
  • Results of clinical trials evaluating (neo)adjuvant anti-VEGF therapy for unfavorable/high-risk localized or locally advanced renal cell carcinoma (RCC)
  • Optimal selection of VEGF-directed therapy for newly diagnosed metastatic RCC (mRCC)
  • Current clinical role of nivolumab in advanced RCC; ongoing trials evaluating immune checkpoint inhibitors in RCC
  • Clinical experience with cabozantinib and current role in the management of advanced RCC; available data with first-line therapy
  • Integration of lenvatinib/everolimus into the care of patients with mRCC
  • Investigational approaches with enzalutamide, abiraterone and sipuleucel-T in patients with nonmetastatic castration-resistant prostate cancer (CRPC)
  • Available Phase III data with and potential clinical role of adding abiraterone/prednisone to standard hormonal therapy for patients with hormone-sensitive metastatic prostate cancer
  • Clinical and biologic factors affecting the sequence and selection of secondary hormonal therapy, immunotherapy and cytotoxic therapy for patients with metastatic CRPC (mCRPC)
  • Current indications for radium-223 chloride in clinical practice and rational combination strategies (eg, other bone-targeted or secondary hormonal therapy)
  • Incidence of somatic or germline mutations in BRCA1, BRCA2 or ATM in patients with mCRPC; ongoing evaluation of PARP inhibition as a therapeutic strategy

MODULE 6: Hodgkin and Non-Hodgkin Lymphomas/
Chronic Lymphocytic Leukemia 1:40 PM – 2:55 PM

  • Selection of up-front treatment for chronic lymphocytic leukemia (CLL) in younger and older patients with normal- and high-risk cytogenetics
  • Emerging research evidence with and nonprotocol role, if any, of maintenance therapy in CLL
  • Practical integration of venetoclax into clinical algorithms; emerging data with use beyond del(17p) disease
  • Novel strategies under investigation in CLL (eg, acalabrutinib, ublituximab, anti-PD-1/PD-L1 antibodies)
  • FDA approval of subcutaneous rituximab and potential clinical utility
  • Efficacy and safety of obinutuzumab-based induction and maintenance therapy for patients with previously untreated follicular lymphoma (FL)
  • Available data with and ongoing evaluation of the “R squared” regimen in FL
  • Recent FDA accelerated approval of copanlisib for relapsed FL and ongoing investigation of novel agents in FL (eg, ibrutinib, venetoclax, denintuzumab mafodotin)
  • Available and emerging research information with novel agents as a component of induction and/or post-transplant maintenance therapy in mantle cell lymphoma (MCL) and treatment options for patients with relapsed/refractory (R/R) disease
  • Preliminary outcomes with brentuximab vedotin (BV) as a component of first-line therapy for patients with Hodgkin lymphoma (HL); practical considerations with the use of BV as a bridge to or as consolidation after transplant
  • FDA approvals of nivolumab and pembrolizumab for patients with R/R HL; ongoing evaluation of immune checkpoint inhibitors alone or in combination with other immunotherapies or targeted agents in HL
  • Available and emerging research information with lenalidomide and ibrutinib in newly diagnosed and R/R diffuse large B-cell lymphoma (DLBCL)
  • Emerging research evidence with and potential clinical role of CAR T-cell therapy for patients with DLBCL and other aggressive lymphomas
  • Patient- and/or disease-specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in T-cell lymphoma
  • Clinical implications and prognostic role of minimal residual disease detection in CLL and various lymphoma subtypes

MODULE 7: Gastrointestinal Cancers 3:10 PM – 4:00 PM

  • Patient and disease characteristics guiding therapy for patients with metastatic colorectal cancer (mCRC), including primary tumor location and presence of potentially targetable genetic abnormalities (eg, BRAF, HER2)
  • FDA approval of pembrolizumab and nivolumab for patients with MSI-high or mismatch repair-deficient tumors; integration into current mCRC treatment algorithms
  • Rational incorporation of regorafenib and TAS-102 into the treatment algorithm for mCRC and early activity and safety data in treatment-refractory gastric cancer
  • Integration of ramucirumab into clinical algorithms for metastatic HER2-negative and HER2-positive gastric/gastroesophageal junction (GEJ) cancer
  • Ongoing evaluation and current off-protocol role, if any, of FOLFIRINOX or nanoparticle albumin-bound (nab) paclitaxel/gemcitabine for patients with pancreatic adenocarcinoma in the neoadjuvant and adjuvant settings
  • Optimal integration of nanoliposomal irinotecan (nal-IRI) into clinical practice
  • Recent FDA approval of pembrolizumab for PD-L1-positive recurrent or advanced gastric/GEJ adenocarcinoma after 2 or more lines of chemotherapy and, if appropriate, HER2-targeted therapy; ongoing trials of anti-PD-1/PD-L1 antibodies alone or in combination with other systemic or immunotherapeutic approaches
  • Implications for clinical practice of the recent FDA approvals of regorafenib and nivolumab for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib
  • Emerging data comparing lenvatinib to sorafenib in patients with advanced, unresectable HCC
  • Clinical utility and optimal employment of long-acting somatostatin analogues for neuroendocrine tumors (NETs)
  • Current clinical role of everolimus for patients with locally advanced or metastatic, nonfunctional NET of lung or gastrointestinal (GI) origin
  • Recent FDA approval of telotristat ethyl for patients with carcinoid syndrome and findings from recent Phase III trials
  • Ongoing investigation of other novel agents and strategies in GI cancers (eg, napabucasin, PEGPH20)

CE Information

Target Audience:
This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers.
  • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, ovarian and select hematologic cancers, and refer appropriate patients for study participation.
  • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
  • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
  • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

Accreditation Statements:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

CME Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE Credit Designation Statements:
This educational activity for 6.6 contact hours is provided by Research To Practice.

This activity is awarded 6.6 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA Certification Information:
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit ResearchToPractice.com/Meetings/YIR2017/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

CME Credit Form:
A credit form will be given to each participant at the conclusion of the activity.

CNE Credit Form:
To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice, the Accreditation Council for Continuing Medical Education or American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Educational Support:
This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Exelixis Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Ipsen Biopharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Takeda Oncology and Tesaro Inc.

Research To Practice staff and external reviewers — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Location

Fairmont Miramar Hotel & Bungalows
101 Wilshire Blvd
Santa Monica, CA 90401
Hotel phone: (310) 576-7777

Meeting Room: Starlight Ballroom (Lobby Level)

Room Reservations:
A special rate of $299 (Standard Deluxe Room) has been arranged for meeting attendees. Please contact the Fairmont Miramar hotel for reservations at (866) 964-7262. A personal credit card will be required to secure accommodations.

Be sure to mention the following reference code when calling the hotel to receive the group rate: Year in Review 2017.

Room reservations must be made by Friday, October 27, 2017. A limited number of rooms are available, and we encourage you to make your reservations early.

Directions:
For driving and public transportion directions to Fairmont Miramar Hotel & Bungalows, please click here.

Registration

This live activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals.

At this time registration for this educational activity is open to clinicians in practice only. If you are a clinician, please continue below to register for this event. There is no registration fee for this event. Preregistration is advised as seating is limited.

For all other professionals,* we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information after clicking the second registration option below. Should seats become available for the program, we will notify you.

Registration for clinicians in practice

I am a practicing physician, nurse, fellow or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
 
STANDBY registration for other/industry professionals*

STANDBY registration for other/industry professionals.*

Standby registration for industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME/CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.